Vol. 12. Núm. 68.
Páginas 3982-3989 (Noviembre 2018)

Actualización
Hipertensión pulmonar en el adulto

Pulmonary hypertension in adults

B. Aldave OrzáizA. Sánchez AzofraT. Alonso PérezF.J. García Pérez
Doi : https://10.1016/j.med.2018.11.012
Opciones
Resumen

La hipertensión pulmonar (HP) es un trastorno fisiopatológico que se asocia a diversas patologías y puede empeorar el pronóstico de la mayoría de las enfermedades cardiovasculares y respiratorias. Se define como un aumento de la presión arterial pulmonar media ≥ 25mm Hg en reposo, calculada mediante cateterismo cardíaco derecho. Para su diagnóstico, se debe confirmar el cumplimiento de los criterios hemodinámicos que definen la existencia de HP y orientar la etiología de la misma. El tratamiento de la HP tiene como objetivo lograr un estado de bajo riesgo de progresión mediante una estrategia compleja que incluye medidas generales, derivación a un centro especializado para inicio de tratamiento dirigido, así como valoración de trasplante pulmonar cuando la enfermedad progresa a pesar del tratamiento médico optimizado.

Palabras clave
Hipertensión pulmonar
Cateterismo cardíaco derecho
Hipertensión arterial pulmonar
Abstract

Pulmonary hypertension (PH) is a pathophysiological disorder related to several conditions which may impair the prognosis of cardiovascular and respiratory diseases. Is defined by a mean pulmonary artery pressure ≥25mm Hg at rest, measured during right heart catheterization. Diagnosis requires that hemodynamic criteria of PH are met and to describe the etiology of the condition. The treatment goal of PH is to achieve a low-risk status by a complex strategy including general measures, referral to expert centers, disease-targeted therapies and lung transplantation decision when disease progresses and gets worse.

Keywords
Pulmonary hypertension
Right heart catheterization
Pulmonary arterial hypertension

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
201812010609073228
201812010609073229
N. Galiè, M. Humbert, J.L. Vachiery, S. Gibbs, I. Lang, A. Torbicki, et al.
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
Eur heart J., (2016), 37 pp. 67-119
[2]
2018120106090732210
2018120106090732211
G. Simonneau, M.A. Gatzoulis, I. Adatia, D. Celermajer, C. Denton, A. Ghofrani, et al.
Updated clinical classification of pulmonary hypertension.
J Am Coll Cardiol., (2013), 62 pp. D34-D41
[3]
2018120106090732212
2018120106090732213
M.D. McGoon, R.I. Benza, P. Escribano-Subias, X. Jiang, D.P. Miller, A.J. Peacock, et al.
Pulmonary arterial hypertension: epidemiology and registries.
J Am Coll Cardiol., (2013), 62 pp. 51-59
[4]
2018120106090732214
2018120106090732215
C.R. Mejía Chew, S. Alcolea Batres, J.J. Ríos Blanco.
Actualización en hipertensión arterial pulmonar.
Rev Clin Esp., (2016), 216 pp. 436-444
[5]
2018120106090732216
Sánchez Gómez JF, Tabernero Huguet E, Ruiz Iturriaga LA. Capítulo 38. Hipertensión pulmonar. Disponible en: https://www.neumosur.net/files/EB03-38%20HTP.pdf.
[6]
2018120106090732217
P. Escribano-Subias, I. Blanco, M. López-Mesenguer, C.J. López-Guarch, A. Roman, P. Morales, et al.
Survival in pulmonary hupertension in Spain: insights from the Spanish registry.
Eur Respir. J., (2012), 40 pp. 596-603
[7]
2018120106090732218
G. Simonneau, N. Galiè, L.J. Rubin, D. Langleben, W. Seeger, G. Domenighetti, et al.
Clinical classification of pulmonary hypertension.
J Am Coll Cardiol., (2004), 43 pp. S5-S12
[8]
2018120106090732219
F. Soubrier, W.K. Chung, R. Machado, E. Grunig, M. Aldred, M. Geraci, et al.
Genetics and genomics of pulmonary arterial hypertension.
J Am Coll Cardiol., (2013), 62 pp. D13-D21
[9]
2018120106090732220
L.J. Rubin, J. Mendoza, M. Hood, M. McGoon, R. Barst, W.B. Williams, et al.
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol).
Results of a randomized trial. Ann Intern Med., (1990), 112 pp. 485-491
[10]
2018120106090732221
N. Galiè, M. Humbert, J.L. Vachiery, C.D. Vizza, M. Kneussl, A. Manes, et al.
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebocontrolled trial.
J Am Coll Cardiol., (2002), 39 pp. 1496-1502
[11]
2018120106090732222
W. Seeger, Y. Adir, J.A. Barberà, H. Champion, J.G. Coghlan, V. Cottin, et al.
Pulmonary hypertension in chronic lung diseases.
J Am Coll Cardiol., (2013), 62 pp. D109-D116
[12]
2018120106090732223
J. Hurdman, R. Condliffe, C.A. Elliot, A. Swift, S. Rajaram, C. Davies, et al.
Pulmonary hypertension in COPD: results from the ASPIRE registry.
Eur Respir J., (2013), 41 pp. 1292-1301
[13]
2018120106090732224
G. Simonneau, R.J. Barst, N. Galiè, R. Naeije, S. Rich, R.C. Bourge, et al.
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial.
Am J Respir Crit Care Med., (2002 Mar), 165 pp. 800-804
[14]
2018120106090732225
P. Trip, E.J. Nossent, F.S. de Man, I.A. van den Berk, A. Boonstra, H. Groepenhoff, et al.
Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses.
Eur Respir J., (2013), 42 pp. 1575-1585
[15]
2018120106090732226
N. Tunariu, S.J. Gibbs, Z. Win, W. Gin-Sing, A. Graham, P. Gishen, et al.
Ventilation-perfusion scintigraphy Is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension.
J Nucl Med., (2007), 48 pp. 680-684
[16]
2018120106090732227
A. Resten, S. Maitre, M. Humbert, A. Rabiller, O. Sitbon, F. Capron, et al.
Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease.
AJR Am J Roentgenol., (2004), 183 pp. 65-70
[17]
2018120106090732228
A.J. Peacock, S. Crawley, L. McLure, K. Blyth, C.D. Vizza, R. Poscia, et al.
Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension–targeted therapy: the EURO-MR Study.
Circ Cardiovasc Imaging, (2014), 7 pp. 107-114
[18]
2018120106090732229
R. Naeije.
Hepatopulmonary syndrome and portopulmonary hypertension.
Swiss Med Wkly., (2003), 133 pp. 163-169
[19]
2018120106090732230
N. Galiè, P. Corris, A. Frost, R.E. Girgis, J. Granton, Z.C. Jing, et al.
Updated treatment algorithm of pulmonary hypertension.
J Am Coll Cardiol., (2013), 62 pp. D60-D72
[20]
2018120106090732231
T. Pulido, I. Adzerikho, R.N. Channick, M. Delcroix, N. Gal, H.A. Ghofrani, et al.
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
N Engl J Med., (2013), 369 pp. 809-818
[21]
2018120106090732232
J.L. Vachiery, S. Huez, H. Gillies, G. Layton, N. Hayashi, X. Gao, et al.
Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.
Br J Clin Pharmacol., (2011), 71 pp. 289-292
[22]
2018120106090732233
O. Sitbon, M. Delcroix, E. Bergot, A.B. Boonstra, J. Granton, D. Langleben, et al.
EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
Am Heart J., (2014), 167 pp. 210-217
[23]
2018120106090732234
T. Higenbottam, A.Y. Butt, A. McMahon, R. Westerbeck, L. Sharples.
Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.
Heart, (1998), 80 pp. 151-155
[24]
2018120106090732235
N. Galiè, J.A. Barbera, A.E. Frost, H.A. Ghofrani, M.M. Hoeper, V.V. Mc Laughlin, et al.
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
New Engl J Med., (2015), 379 pp. 834-844